| Categories, non-susceptible |  | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Isolate | Penicillins | β-lactam combination agents | Cephems | Carbapenems | Fluoroquinolones | Folate pathway antagonists | Macrolides | Tetracyclines | Glycylcyclines | MDR |
ED01 | ||||||||||
ED02 | Â | Â | Â | Â | Â | SXT | Â | TE | Â | Â |
ED03 | Â | Â | Â | Â | CIP, LVX | SXT | Â | Â | Â | Â |
ED04 | AM | Â | Â | Â | CIP, LVX | SXT | AZM | Â | Â | V |
ED05 | AM | Â | Â | Â | CIP, LVX | SXT | Â | Â | Â | V |
ED06 | AM | AMC | CXM | Â | Â | SXT | Â | Â | Â | V |
ED07 | AM | Â | CXM | Â | Â | SXT | Â | TE | Â | V |
ED08 | AM | Â | Â | Â | Â | SXT | Â | TE | Â | V |
ED09 | AM | Â | CXM | Â | CIP, LVX | SXT | Â | Â | Â | V |
ED10 | AM | Â | Â | Â | CIP, LVX | SXT | Â | TE | Â | V |
ED11 | ||||||||||
ED12 | ||||||||||
ED13 | AM | AMC | CXM | Â | Â | Â | Â | Â | Â | V |
ED14 | ||||||||||
ED15 | AM | Â | Â | Â | CIP, LVX | SXT | Â | TE | Â | V |
ED16 | Â | Â | Â | Â | CIP, LVX | SXT | Â | Â | Â | Â |
ED17 | Â | Â | Â | Â | CIP, LVX | SXT | Â | Â | Â | Â |
ED18 | Â | Â | CXM | Â | CIP, LVX | SXT | Â | Â | Â | V |
ED19 | AM | AMC | CXM | Â | Â | SXT | Â | Â | Â | V |
ED20 | ||||||||||
ED21 | Â | Â | Â | Â | CIP, LVX | SXT | Â | Â | Â | Â |
ED22 | AM | AMC | CXM | Â | CIP, LVX | SXT | Â | Â | Â | V |
ED23 | AM | Â | CXM | Â | CIP, LVX | SXT | Â | Â | Â | V |
ED24 | Â | Â | Â | Â | CIP, LVX | SXT | Â | Â | Â | Â |
ED25 | Â | Â | Â | Â | CIP, LVX | SXT | Â | Â | Â | Â |
ED26 | Â | Â | Â | Â | CIP, LVX | SXT | Â | Â | Â | Â |